Long-term outcome of enzyme-replacement therapy in advanced Fabry disease: evidence for disease progression towards serious complications

Por Weidemann, F, Niemann, M, Störk, S, Breunig, F, Beer, M, Sommer, C, Herrmann, S, Ertl, G, Wanner, C
Publicado no J Intern Med (2013)

Myocardial lipid content in Fabry disease: a combined (1)H-MR spectroscopy and MR imaging study at 3 Tesla

Por Petritsch, B., Köstler, H., Weng, A. M., Horn, M., Gassenmaier, T., Kunz, A. S., Weidemann, F., Wanner, C., Bley, T. A., Beer, M.
Publicado no BMC Cardiovasc Disord (2016)

Recommendations on Reintroduction of Agalsidase Beta for Patients with Fabry Disease in Europe, Following a Period of Shortage

Por Linthorst, Gabor E., Burlina, Alessandro P., Cecchi, Franco, Cox, Timothy M., Fletcher, Janice M., Feldt-Rasmussen, Ulla, Giugliani, Roberto, Hollak, Carla E. M., Houge, Gunnar, Hughes, Derralynn, Kantola, Iikka, Lachmann, Robin, Lopez, Monica, Ortiz, Alberto, Parini, Rossella, Rivera, Alberto, Rolfs, Arndt, Ramaswami, Uma, Svarstad, Einar, Tondel, Camilla, Tylki-Szymanska, Anna, Vujkovac, Bojan, Waldek, Steven, West, Michael, Weidemann, F., Mehta, Atul
Publicado em 2012